Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
CC transcript
ALNYLAM PHARMACEUTICALS, INC. (ALNY) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis"
09/28/2023 8-K Quarterly results
08/07/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Letter Agreement, between Alnylam Pharmaceuticals, Inc. and Akshay K. Vaishnaw, M.D., Ph.D",
"Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity"
07/26/2023 8-K Quarterly results
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO ® for the Treatment of the Cardiomyopathy of ATTR Amyloidosis"
05/23/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/28/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 ARS Form ARS - Annual Report to Security Holders:
04/03/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/03/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity"
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a 3.3% stake in ALNYLAM PHARMACEUTICALS INC
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.4% stake in Alnylam Pharmaceuticals Inc.
02/09/2023 SC 13G/A FMR LLC reports a 11% stake in ALNYLAM PHARMACEUTICALS INC
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/31/2023 SC 13G/A BlackRock Inc. reports a 7% stake in ALNYLAM PHARMACEUTICALS INC
01/19/2023 SC 13G/A BAILLIE GIFFORD & CO reports a 7.6% stake in ALNYLAM PHARMACEUTICALS
01/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates"
01/06/2023 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Updates to its Board of Directors"
10/27/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/27/2022 8-K Quarterly results
09/16/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Indenture, between Alnylam Pharmaceuticals, Inc. and The Bank of New York Mellon, as trustee",
"Form of Capped Call Transaction Confirmation"
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes",
"Alnylam Announces Pricing of Offering of $900 Million Convertible Senior Notes"
09/09/2022 SC 13G Capital World Investors reports a 10.7% stake in Alnylam Pharmaceuticals, Inc.
08/24/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/28/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/28/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy